Allogene Therapeutics, Inc. (ALLO)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
ALLO price, last 12 months
Key stats
- Previous close
- $0.6959
- Open
- $0.6960
- Day range
- $0.6500 – $0.7174
- 52-week range
- $0.6192 – $4.46
- Volume
- 7.4M
- Avg volume (20 days)
- 12.1M
- Market cap
- $290.6M
Performance
Technicals and fundamentals
About Allogene Therapeutics, Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $290.6M